Kobe Regenerative Medicine Study Group

Member Company Introduction 2026

Table of Contents

List of FY 2026 Member Companies *in 50 Japanese syllabary order

Regular Member

Company Profile Listing

		JP	EN
1	IQVIA Services Japan G.K.	●	●
2	Iwatani Corporation	●	—
3	Air Water Aeras Bio Inc.	●	●
4	Otsuka Pharmaceutical Co., Ltd.	—	—
5	Oncolys BioPharma Inc.	—	—
6	KANEKA CORPORATION	●	●
7	KITAYAMA LABES CO.,LTD. KOBE biomedical laboratory	—	—
8	Cyto-Facto Inc.	●	●
9	CynosBio, Inc.	—	—
10	ZACROS Corporation	●	●
11	SANKEN SETSUBI KOGYO CO., LTD.	●	●
12	JCR Pharmaceuticals Co., Ltd.	●	●
13	SYSMEX CORPORATION	—	—
14	SINFONIA TECHNOLOGY CO., LTD.	●	●
15	SUZUKEN CO.,LTD.	●	●
16	Seiken Co.,Ltd.	●	●
17	DAI-DAN CO., LTD.	●	—
18	ViSpot Division, Takara Bio Inc.	●	●
19	DUNLOP	—	—
20	TMI Associates	●	●

Company Profile Listing

		JP	EN
21	Texcell Japan KK	●	●
22	TechnoPro, Inc. TechnoPro R&D, Company	●	●
23	TOPPAN Inc.	●	●
24	NARD Institute, Ltd.	●	●
25	Nissin Corporation	●	●
26	Japan Blood Products Organization	●	●
27	NextGeM Inc.	●	●
28	Vision Care Group (VCCT Inc.／Vision Care Inc.／VCGT Inc.)	●	●
29	Hitachi, Ltd.	●	●
30	PHICELL Corporation	●	●
31	FUJIFILM Corporation	—	—
32	Bourbon Corporation	●	●
33	VectorBuilder Japan, Inc.	●	●
34	HEALIOS K.K.	●	●
35	Matrixome Inc.	●	●
36	Mizuta Seisakusho Co., Ltd.	●	—
37	MITSUI-SOKO HOLDINGS Co., Ltd.	●	●
38	RACTHERA Co., Ltd.	●	●
39	BioResource Innovation Hub in Kobe	●	—

Supporting Member

Company Profile Listing

		JP	EN
41	Otsuka Pharmaceutical Factory, Inc.	—	—
42	CM Plus Corporation	●	●

Company Profile Listing

		JP	EN
43	Mediford Corporation	●	●

Introduction to the Kobe Regenerative Medicine Study Group

Global Center for Regenerative Medicine in KOBE Biomedical Innovation Cluster





■Role of Kobe Regenerative Medicine Study Group

Information Gathering and Networking

- Collecting the Latest Information
- Mutual Information Exchange
- Promoting Exchange among Companies

Promoting Industrialization of Regenerative Medicine Business

- Resolving Issues for Practical Application of Regenerative Medicine
- Mutual Understanding of Technologies Related to Regenerative Medicine

Establishing a Global Center for Regenerative Medicine in KOBE Biomedical Innovation Cluster

■Management Structure of Kobe Regenerative Medicine Study Group

Member ※

■ ①Regular Member
Regenerative medicine-related companies that have a base in KOBE Biomedical Innovation Cluster, as well as those with their headquarters or main offices located within the Kobe city.
②Supporting Member
Regenerative medicine-related companies not falling under category ①, which collaborate to support the activities of the study group.

■ (In principle) Up to 6 members can participate

■ Annual fee: ①Regular Member 50,000 yen/company
②Supporting Member 100,000 yen/company

※The annual fee will be reduced or waived if the content of the activities changes due to unavoidable reasons.
Companies interested in joining are, in principle, permitted to attend one study session as provisional members.

Observer

■ Invite temporary observers as needed

■ From research institutes, universities, public offices, hospitals, etc.
Appointed by the secretariat in consideration of the requests, etc.

Management System
Secretariat (planning and management): Foundation for Biomedical Research and Innovation at Kobe

Content of Activities
・4 study meetings per year (in principle)
・Structure: Lecture + company presentation + social gathering
・Includes special events, individual consultation, matching, etc.

Past Activities of the Study Group

Activities

FY2024

The First Event : Monday, May 27	
Shinshu University	Yozo Nakazawa
C4U CORPORATION	Akimitsu Hirai
PtBio Inc.	Keisuke Okuhara
Company Introduction	
Bourbon Corporation TechnoPro, Inc. TechnoPro R&D, Company	
The Second Event : Monday, September 30	
Ministry of Health, Labour and Welfare	Kazuki Morita
Pharmaceuticals and Medical Devices Agency	Emiko Hirayama
Novartis Pharma K.K.	Hirohito Katayama
Company Introduction	
FUJIFILM Corporation Toray Research Center, Inc.	
The Third Event : Thursday, March 13	
National Institute of Health Sciences	Akiko Ishii
The Jikei University School of Medicine	Saki Matsushima
National Cancer Center	Tetsuya Nakatsura
National Center for Child Health and Development	Masafumi Onodera
Company Introduction	
Allied Laboratories Co., Ltd. JFE Techno-Research Corporation TMI Associates TOPPAN Inc. Kansai Bureau of Economy, Trade and Industry	

FY2025

The First Event : Friday, May 23	
The Institute of Medical Science, The University of Tokyo	Tomoki Todo
Pharmaceuticals and Medical Devices Agency	Akira Sakurai
Company Introduction	
Mediford Corporation CM Plus Corporation	
The Second Event : Friday, September 25	
CM Plus Corporation	Hirohito Katayama
Ministry of Health, Labour and Welfare	Kaita Fujihara
Company Introduction	
MITSUI-SOKO HOLDINGS Co., Ltd IQVIA Services Japan G.K.	
Introduction	
Kansai Bureau of Economy, Trade and Industry	
The Third Event : Wednesday, March 25	
National Institute of Health Sciences	Yoji Sato
National Institute of Health Sciences	Satoshi Yasuda
Company Introduction	
Phicell Corporation Sumika Chemical Analysis Service, Ltd.	

Special Event

This event is open to non-members.
Once a year, a hybrid event is held in Tokyo under the name of "Regenerative Medicine Industrialization Forum."

FY2025:Tuesday, February 10, 2026
Meeting Venue:
(Tokyo Venue) Nihonbashi Life Science HUB

*Please check the event details at the following URL
https://www.fbri-kobe.org/news/detail.php?news_id=1433
※Japanese site

Topics on Regenerative Medicine in KOBE Biomedical Innovation Cluster

RACTHERA Co., Ltd.

RACTHERA　HITACHI

Approval for manufacturing and marketing authorization of the allogeneic iPS cell-derived dopaminergic neural progenitor cell product "AMCHEPRY®" was obtained (March 2026: Sumitomo Pharma).
The product is manufactured using an automated cell culture system developed by Hitachi, Ltd.

RACTHERA　News
https://www.hitachi.com/en/press/articles/2019/03/0311/

FUJIFILM Corporation

FUJIFILM Value from Innovation　CF サイト・ファクト

Manufacturing and marketing approval for the autologous synovial mesenchymal stem cell product "SAVYSCUS® Injection" was granted in May 2026.
During clinical trials, the investigational product was manufactured by Cyto-Facto Inc. under contract (formerly the Research and Development Center for Cell Therapy (RDC), Foundation for Biomedical Research and Innovation at Kobe).

https://www.fujifilm.com/jp/en/news/hq/13571
https://www.fbri-kobe.org/upload/view.php?news_id=1126&type=main
※Japanese site

Member Company Profiles *in 50 Japanese syllabary order

*Click on a company name to view more details.

Company Name	Information Pages	Regenerative Medicine Research and Development	Drug Discovery	Incubator	Culture Medium/ Culture Solution	Culture Device	Air Conditioning / CPC	Quality/Analysis Contract	Contract Research Organization (Non-Clinical/Clinical)	Logistics	Patent Offices, etc.	Others
Regular Member												
IQVIA Services Japan G.K.	5							●				
Air Water Aeras Bio Inc.	6	●										●
KANEKA CORPORATION	7	●						●				●
Cyto-Facto Inc.	8	●				●	●	●	●			●
ZACROS Corporation	9	●		●		●						
SANKEN SETSUBI KOGYO CO., LTD.	10						●					
JCR Pharmaceuticals Co., Ltd.	11	●	●									
SINFONIA TECHNOLOGY CO., LTD.	12					●						
SUZUKEN CO.,LTD.	13									●		
Seiken Co.,Ltd.	14						●					
ViSpot Division, Takara Bio Inc.	15							●	●			
TMI Associates	16										●	●
Texcell Japan KK	17							●				
TechnoPro, Inc. TechnoPro R&D, Company	18		●					●				
TOPPAN Inc.	19											●
NARD Institute, Ltd.	20	●	●	●	●							
Nissin Corporation	21									●		●
Japan Blood Products Organization	22		●									
NextGeM Inc.	23	●	●		●			●				●
Vision Care Group (VCCT Inc.／Vision Care Inc.／VCGT Inc.)	24	●										
Hitachi, Ltd.	25	●				●	●					
PHICELL Corporation	26							●		●		●
Bourbon Corporation	27	●			●							
VectorBuilder Japan, Inc.	28							●	●			●
HEALIOS K.K.	29	●	●									
Matrixome Inc.	30	●										●
MITSUI-SOKO HOLDINGS Co., Ltd.	31									●		
RACTHERA Co., Ltd.	32	●	●									
Supporting Member												
CM Plus Corporation	33											●
Mediford Corporation	34	●						●	●	●		●

IQVIA Services Japan G.K.

Provide services to support Clinical research / Clinical trial in Human (CRO)

IQVIA implements wide variety of solutions for help regenerative medicine products from research stage to post marketing stage.



IQVIA is a leading global healthcare provider, accelerating innovation for a healthier world



Innovative Therapy Clinical Development Office

Provides fully integrated services based upon extensive experiences of global development, clinical monitoring for verity of disease, ICCC, regulatory consulting.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients.

CONTACT US

IQVIA Japan Group IQVIA Services Japan G.K
Keikyu Dai-1 Bldg., 4-10-18 Takanawa, Minato-ku, Tokyo
TEL : 03-6859-9500 E-mail : Japan@iqvia.com URL: www.iqvia.co.jp

Quality/ Analysis Contract

Air Water Aeras Bio: The Future of Regenerative Medicine with Dental Pulp Stem Cells

Air Water Aeras Bio is promoting the "Dental Pulp Stem Cell Bank Project," which involves cryopreserving "dental pulp stem cells" collected from extracted baby teeth and wisdom teeth in preparation for future regenerative medicine, and is also promoting the spread of regenerative medicine using dental pulp stem cells. Teeth that were previously discarded are now transformed into "hope" that will save your future and the future of your family.

Why are we focusing on "dental pulp stem cells"?

1 Less invasive to the body during cell collection



Dental pulp stem cells can be harvested from "baby teeth" and "wisdom teeth" that are extracted and discarded at dental clinics, making them less invasive to the body compared to stem cell harvesting from bone marrow or fat.

2 Possesses excellent proliferative and nerve repair capabilities.



Dental pulp stem cells are stem cells derived from the neural crest and are known to have a high capacity to release factors (such as BDNF) that contribute to the repair and regeneration of nerve tissue. In addition, stem cells collected from deciduous teeth are particularly young and have excellent proliferative capacity.

3 Possesses the ability to differentiate into diverse organizations.



It has the ability to differentiate into various tissue cells, including nerve cells, blood vessel cells, and bone cells, and holds great potential to be useful in treating a wide range of diseases and injuries in the future.



"Aeras Bio Dental Pulp Stem Cell Bank™"

The dental pulp stem cell bank service is a mechanism that bridges the time gap between "when cells can be collected" and "when they can actually be used."
It can also be seen as a "medical time capsule" where you can leave cells for yourself or your family in the future.

Prepare for the future when your teeth start to fall out.

Our company offers a new option to prepare for unexpected illnesses or injuries: entrusting us with your and your family's young and healthy cells. The dental pulp stem cells you entrust to us have the potential to be used not only in dental pulp regeneration therapy (treatment to regenerate tooth nerves), which is already in practical use, but also in various regenerative medicine applications in the future, such as treatment for spinal cord injuries, strokes, dementia, autism, and jawbone regeneration.

Reliable technology and a foundation of peace of mind for a lifetime.

Air Water Aeras Bio is a group company of Air Water Inc., and is backed by the comprehensive capabilities and infrastructure of the "Air Water Group," which has supported the Japanese medical field for many years with medical gases and state-of-the-art hospital equipment.
It is thanks to our advanced temperature control technology and strong management foundation that we can safely store your dental pulp stem cells for decades into the future.

For inquiries and requests for materials, please use the inquiry form on our website.
Air Water Aeras Bio Co., Ltd.

HP

Instagram

Facebook

Kaneka Corporation

Creating materials and products that can contribute to people's health and medical care

[Product and Technology]
Human Amnion-Derived Mesenchymal Stem Cells

Features of Kaneka Amniotic MSC

- Manufactured using mass culture technology
  → Large quantities of cells from the same donor can be prepared, enabling mass production and stable supply
- CPC for Kaneka Amniotic MSC production has obtained a specific cell processing license and is compliant with GCTP
  → Can be developed for clinical application and can be used for commercial use in the future

Features of amniotic membrane and amniotic MSC

- Amniotic membrane is procured from domestic medical institutions.
  → Can be used as a cell source for domestically produced cell preparations.
- Animal experiments have confirmed that amniotic membrane MSCs are hypoimmunogenic and have immunosuppressive and tissue repair effects.
  → Expectations for cell medicine applications.



PluriAIR™, a new floating mass culture technology for pluripotent stem cells

Technology Overview

A novel suspension culture technology for pluripotent stem cells(iPS/ES cells) (Patent No.6238265)

①Cell Agglomeration control : Technology for adjusting the size of cell aggregates
②Undifferentiated Maintenance : Technology to suppress spontaneous differentiation
③Process Development : Developing a manufacturing process using bioreactors with GMP manufacturing experience



Contact: Kaneka Institute for Regenerative Medicine, Inc. Tomoyuki Nakaishi
Kobe MI R & D Center 3 F, 6 -7 -3 Minatojimaminami-machi, Chuo-ku, Kobe, 650 0047
TEL: 050-3133-7903 Mail: Tomoyuki.Nakaishi@kaneka.co.jp[LINK1]
General website for regenerative medicine:
https://www.kaneka.co.jp/saiseisaibo/index.html

Cyto-Facto is a CDMO specializing in gene and cell products. We provide one-stop, high-quality services from initial development to commercial product manufacturing.

Cyto-Facto



Services

Process development, clinical trial product manufacturing, commercial product manufacturing (CMO/CDMO)

Operating multiple PICS GMP-compliant cell manufacturing facilities
Providing global standards based on our experience in commercial production of CAR-T products

Consigned quality testing and characterization

Quality control tests, analytical validation, and the launch of test systems in compliance with the Japanese Pharmacopoeia and GCTP/GMP

Our Manufacturing Sites



S

Please feel free to contact us first.

www.cytofacto.com/contact/

info@cytofacto.com

Cyto-Facto Inc.
3rd Floor, Shimin byoin mae Bldg.,
-1 -11 Minatojima-minami-cho 2, Chuo-ku, Kobe, Hyogo 650 0047, Japan
www,cytofacto.com

ZACROS Corporation

BioPhaS®

Single-use products for manufacturing of Biopharmaceuticals and Regenerative medicine.
--R&D to manufacturing--

Single-use products BioPhaS®

No cleaning & sterilization No validation	Reduction risk of residues & cross-contamination
Possible the multi-item production	Reduction of construction period & costs

Manufacturing

・Highly clean enviroment
・Error-proof system
・GMP-compliant

Service

・Customization
・Prototype provision
・Validation/E&L data

+

Orbital-shaking fermenter Tres Cuna™

Mass culture for stem cell
・Low shear stress
・Scale up 0.03～2,000 L

Closed system
・Single-use technology

GMP compliant
・Temperaature, pH, DO control/recording

Construction of mass culture processes for mammalian cells

・Regenerative medecine
human cells : iPSC、MSC etc.
・CHO for antibody manufacturing
・Virus production for gene therapy
・Cultured meat



Contribute industrialization of regenerative medicine, as a domestic manufacturer of single-use products

6-3-5, Minatojima minami-machi, Chuou-ku, Kobe
TEL:078-302-3307

SANKEN SETSUBI KOGYO CO., LTD.

Reliable Technical Expertise for CPC Facility Development

One-Stop Solutions: From Planning to Maintenance

Sanken Setsubi Kogyo applies advanced technical expertise, built on extensive experience and a proven track record, to meet the specialized demands of regenerative medicine and cell processing facilities. We offer detailed, end-to-end services across the entire facility lifecycle. These include GMP and GCTP-compliant planning and design, operations-aligned maintenance, and facility upgrades and renewals. Our comprehensive support ensures the creation of optimal environments.



Reliable Facility Proposals with a Solid Track Record

Built on the same Three Principles of GMP we apply to pharmaceutical plants, our approach to cell processing facilities combines advanced technical expertise with end-to-end project management. From workflow planning to quality assurance, we deliver tailored solutions. Our industry-leading Testing, Adjusting, and Balancing (TAB) capabilities ensure secure, high-performance environments with precise room pressure and aseptic conditions.

https://skk.jp/en/

Head Office
4F MSH Nihonbashi Hakozaki Building, 19-21 Nihonbashihakozaki-cho, Chuo-ku, Tokyo
103-0015 TEL 03-6280-2561

Kobe Sales Office
Sanko Bldg. 7th Floor, 5-1-24 Isokami-dori, Chuo-ku, Kobe, Hyogo, 651 0086
TEL 078-515-6240

JCR Pharmaceuticals Co., Ltd.

"We create treatments that go beyond rare disease to solve the world's most complex healthcare challenges"

Strengths in Cell Therapy and Regenerative Medicine Technologies



Striving to Realize New Value Only We Can Deliver

- First in Japan to obtain manufacturing and marketing approval for an allogeneic regenerative medicine product
- Over a decade of expertise in regenerative medicine product manufacturing
- Proprietary platform technologies for both cell and gene therapies
- End-to-end capabilities from R&D to manufacturing and commercialization

Advancing Cell, Regenerative & Gene Therapies'

Jan 2021: Bio Research Center
Apr 2026: Biopharmaceutical Research Institute (Creative Lab Kobe (CLIK), Rooms 601–602)

JCR Pharmaceuticals

Life is Rare

JCR Pharmaceuticals Co., Ltd.
Headquarters: 3-19 Kasuga-cho, Ashiya, Hyogo 659-0021, Japan
URL: https://jcrpharm.com/
Contact us: ir-info@jp.jcrpharm.com

Fully automated cell manufacturing instrument

CellQualia™

INTELLIGENT CELL PROCESSING SYSTEM

Joint development with the Foundation for Biomedical Research and Innovation (FBRI) at Kobe

Foundation for Biomedical Research and Innovation at Kobe

- Automated cell culture from seeding to harvesting
- Closed system
- In-line process analysis technologies
- Auto-sampling for off-line analysis
- Auto-passaging
- Real-time imaging
- Solution Lab in KOBE

Kobe Center for Medical Innovation KCMI (Japan)

More information > CellQualia™ Official site | www.cellqualia.com

SINFONIA TECHNOLOGY CO., LTD.

Medical Group
Control and Imaging Products Sales Department
Shiba Tower, 1-30, Shibadaimon 1-chome, Minato-ku, Tokyo, 105-8564, Japan
TEL +81-3-4223-0100 FAX +81-3-5473-1845

SUZUKEN CO., LTD.

We support the distribution and distribution of regenerative medicine products from clinical trials to commercial products.



[our company's strengths]

1.Logistics: Available for transport and delivery from investigational drug to product launch (direct delivery to medical institutions is also available)
2.Commercial distribution: Available from delivery to medical institutions nationwide to billing and collection agency
3.Information: Distribution management is possible using the patient traceability system "R-SAT"

[Company history]

1932	2005	2012	2016	2019	2022
Founded as a pharmaceutical wholesaler	First pharmaceutical wholesaler to start logistics contract business for manufacturers	First pharmaceutical wholesaler Orphan disease field Comprehensive support business Started	Commenced consignment of regenerative medicine	Regenerative medicine platform Construction	Regenerative medicine distribution management system Construction

[News Release]

May 9, 2022 : Patent obtained for R-SAT, a distribution management and administration schedule support system for regenerative medicine products jointly developed with SanBio Inc.

May 20, 2020 : Announcement of Consignment of Distribution in Japan of Zolgensma Intravenous Infusion for Gene Therapy for Spinal Muscular Atrophy

August 5, 2019 : Announcement of Conclusion of Basic Agreement for Distribution of Regenerative Cell Drugs and Commencement of Joint Development of Patient Support System

May 16, 2019 : Announcement of Consignment of Distribution in Japan of Japan's First CAR T Cell Therapy

September 25, 2018 : Announcement of Logistics Collaboration in the Regenerative Medicine Products Field between Suzuken and World Courier

[Contact]
In Charge of Regenerative Medicine Products Promotion: Morishita, Nishimura
e-mail)reg_med@suzuken.co.jp

April, 2026

Striving for a Better Environment with Technology

Seiken Co., Ltd.

Labox®

Bringing Healthcare Closer

To Existing Facilities
Can Be Installed In A Short Time And At Low Cost!
Tucked Into A Small Box
All-in-one clean room

Compact
Low Cost
CPC

Standard Model
12.0 ㎡
Laboratories, clinics, etc.

Panel assembly and air conditioning installation (Duct equipment, fans, HEPA filter units, pass boxes, room pressure control dampers) included



Can be installed in existing buildings

Duct installation, clean equipment and control all in one place Monitoring system * can also be installed

*Optional

Filters provide clean air and provide appropriate differential pressure control

Responding to the GCTP Ministerial Ordinance

Space-saving Low-cost

An all-in-one CPC unit that combines a dressing room, culture room, and dressing room into a compact, CPC unit and can be completed in a short period of time

Patent pending

expansion piece



Patent pending

ductless

1 Double wall clean room and room dampers are installed on the walls of rooms that require room pressure control.

2 Room pressure can be controlled ductless for each room by room damper and variable supply air volume.





easy connection

high visibility

connect more and more

Contact us ▷▷▷

Medical Facility Team

TEL 06-6224-0753

MAIL cpc@seikenn.co.jp

Seiken celebrated its 75 year anniversary in 2022

■Osaka Head Office	〒542-0081	Osaka, Chuo-ku, 2 -1 -3
■Tokyo Head Office	〒112-0002	1 -15 -17 Koishikawa, Bunkyo-ku, Tokyo
■Kobe Sales Office	〒650-0046	6 -9 -1 Minatoshima Nakamachi, Chuo-ward, Kobe-city, Hyogo
■Shikoku Sales Office	〒772-0012	242 Maehama, Kokuwajima, Muya-cho, Naruto City, Tokushima
■Kyushu Sales Office	〒812-0013	1 -14 -25 Hakataeki-higashi, Hakata-ku, Fukuoka-shi, Fukuoka

Based on customer feedback, we tailor CPC designs to meet the needs of new construction and renovation life cycles.
We tailor CPC designs and provide total engineering support.
Once the facility is in operation, regular validation and maintenance will be conducted to ensure that the facility can be used with confidence as long as the facility continues to operate.

"Anytime!" "Forever!" Working Together Seiken contributes to the development of regenerative medicine through its facilities

ViSpot Division, Takara Bio Inc.

Aiming to be Japan's Leading Viral Safety Testing Company

ViSpot MISSION

Viral Safety Testing in Kobe

ViSpot's mission is to provide convenience, speed, and peace of mind.

Through contract viral safety testing services ViSpot will contribute to the development and launch of bioPharmaceuticals in Japan.



Safety assessment test service provided by ViSpot

Virus testing + **Virus clearance study**

Virus safety assessment test is a biopharmaceutical supply chain



ViSpot LABORATORY

ViSpot locations

ViSpot operates mainly in 2 locations: Kobe Lab, located approximately 5 minutes from Kobe Airport, and Rokko Lab, which was expanded in spring 2024.

Kobe Lab
6 -3 -5 KCMO, Minatoshima Minami-cho, Chuo-ku, Kobe
Port Liner,
Computational Science Center Station,
Kobe Medical Innovation Center (KCMI)
Total area: approx. 320 m²
Internal/Customer BSL 2 Laboratory, Offices

Rokko Lab
7 Koyocho Naka-chome, Higashi-minato-ku, Kobe
Rokko Liner,
Island Center Station
5 minutes walk
Asia One Center (AOC)
Total area: approx. 550 m²
BSL 2 Laboratory, Offices

ViSpot

Contact Us

Phone: 078-515-6401
Website: https://www.takara-bio.co.jp/research/info/vispot.htm

Quality/Analysis Contract

Contract Research Organization (Non-Clinical/Clinical)

TMI Associates

Our Legal Practice

Healthcare Industry + Legal Practice

One-Stop Total Legal Services

TMI Associates provides optimal legal services based on deep expertise and extensive experience, with thorough understanding of industry knowledge and technologies necessary to address complex legal issues in the healthcare business field.

Pharmaceutical Regulations

Medical Regulations

Public Insurance

Research Ethics
Conflicts of Interest

FDARegulations
US Healthcare Compliance

Healthcare Business Sector
Legal Issues
Deep Expertise

Intellectual Property

Healthcare Data Regulations

M&A Investment



License Agreements
Joint Research Agreements

Startups IPO

Collaborative Team of
Attorneys & Patent Attorneys



Advertising & Labeling Review
Promotion Codes

Medical Litigation
Drug Liability Litigation

Fraud Investigations
Regulatory Response

Medical Facility Bankruptcy & Rehabilitation

Medical Facility HR & Labor

Global
Support Network

Building on equal partnership agreements with leading international law firms, we have established a rich and robust global network.

simmons simmons　Morgan Lewis　ARQIS FOREIGN LAW OFFICE

Foreign Law
Joint Ventures

Legal Consultation Support

Our firm offers free legal consultation sessions for companies and organizations (including medical and research institutions) based in the Kobe Medical Industry City or within Kobe City, providing legal support useful for business strategy development. Experts offer initial advice on legal issues arising in business operations and R&D, proposing appropriate solutions to help avoid legal risks and facilitate smooth business operations. All areas of law are covered — please feel free to make use of this service.

InformationHP: https://www.fbri-kobe.org/kbic/event/detail.php?event_id=825

TMI Associates
Kobe Office
Address: 〒650-0001
Kano-cho, Chuo-ku, Kobe, Hyogo4-2-1
Kobe Sannomiya Hankyu Building12F
TEL: 078-325-5544 FAX :078-325-5543

Kobe Office
Managing Partner: Takuto Kobayashi
Email: kobe@tmi.gr.jp
HP: https://www.tmi.gr.jp/

Texcell

Texcell. Your Products. Our Passion.

One Stop Provider

Complete Support up to Market and Beyond

Started as a Spinoff of PASTEUR INSTITUTE created in 1987 Texcell SA was established in 2003

Preclinical
- R&D Cell culture
- Single cell-cloning
- Immuno Bioassay
- NGS

Phase 1
- GMP MCB･WCB Manufacturing
- GMP Safety Testing
- GLP Viral Clearance
- NGS

Phase 2
- GLP Viral Clearance
- Testing Design Optimization
- Immuno Bioassay

Phase 3
- GLP Viral Clearance
- GMP Safety Testing
- Immuno Bioassay

Phase 4
- Batch Release
- Immuno Bioassay
- Potency Assay

Global Texcell services pre-clinical/clinical trial to beyond Market Release

Texcell Japan Sales/Director JOGUIN Matthieu
070-3199-6601 mjoguin@texcell.fr

Quality/ Analysis Contract

Technopro R & D Co., Ltd.
Kobe Research Center

For research and development of regenerative medicine drugs, cells, devices,and technologies

Please use Technopro R & D's contract research and experiment service!

Features of our company contract service

•**Wide range of support areas**	We can handle a variety of tests, from molecular to animal experiments!
•**Many contracts**	We contract more than 300 tests per year!
•**High trust**	Many customers use our service multiple times!

[Brokerage Services]

In addition to the following, we can handle a wide range of tests according to your requirements. Please feel free to contact us.

Group	corresponding technology	Specific test examples
gene 	・Plasmid design and preparation (Forced generation, gene editing, etc.) ・Virus design and preparation (Lentivirus, AAV, etc.) ・Mutation and sequence analysis	**Viral plasmid construction (From 1.2 million yen, delivery time around 3 months)** DNA fragments are spliced together in budding yeast to prepare a plasmid containing the viral genome (>20kb) without infectivity.
protein 	・Expression purification of recombinant proteins ・Protein purification from biological samples ・Peptide synthesis ・Analysis of protein and peptide properties	**Protein array construction (From 4 million yen, delivery time around 3 months) Protein arrays composed of arbitrary protein groups are constructed using a wheat germ cell-free system.**
cell 	・Cell culture (Primary cultures, three-dimensional skin models, cell lines, etc.) ・Cell production (Gene editing, knockdown, forced expression, etc.) ・Expression analysis (Real-time PCR, Western blot, etc.) ・Functional analysis (Proliferation, cell death, phosphorylation, differentiation, etc.)	**Gene KO cell construction** (From 2.5 million yen, delivery time around 5 months) Guide RNA for the specified gene is designed using CRISPR/Cas9 system, and knockout (KO) cells are constructed.
Equipment and reagents 	・Inspection of culture equipment (Cell adhesion, endotoxin test, etc.) ・Evaluation of equipment (Performance evaluation, protocol development, etc.) ・Evaluation of experimental reagents (Performance comparison with other companies' products, third-party evaluation, etc.)	**Endotoxin test (From 340,000 yen, delivery time about 1 month)** Eight culture-related instruments are tested for the presence of endotoxin.
Screening 	・Cell-free assay (TR-FRET, HTRF, AlphaScreen, etc.) ・Cell-based assay (Luciferase, NanoBit, etc.)	**Inhibitor screening (From 6 million yen, delivery time around 2 months)** The HTRF reaction system is used to measure protein-protein interactions. Add each of the 500,000 compounds provided and measure the reaction.
natural product purification 	・Crushing and extraction (Crushing of raw materials, removal of precipitates, extraction and concentration) ・Purification (Separation, precipitation, recrystallization, chromatography, etc.)	**Glycolipid purification (From 2.5 million yen, delivery time around 2 months)** Purification of 5 g or more of specific glycolipids from plant materials by organic solvent extraction and various chromatography (purity ≥ 95%).
MEA 	・Neurotoxicity/pharmacology evaluation in iPSC neurons AI & MEA-based Drug Safety/Pharmacology	**Correlation between neurotoxicity risk assessment and animal studies (6 million ~, delivery time around 4 months)** Human iPSC neurons were exposed to test substances and positive/negative control compounds. The data obtained were analyzed by AI to evaluate the central toxicity profile.

More information: https://www.technopro.com/rd/services/contract/

Commissioned research and experiments in the biotechnology and pharmaceutical fields

[Contact]
Masahiko Hirooka, Technopro Technopro R & D Kobe Research Center
Kobe International Business Center 505, 5 -5 -2 Minatoshima Minami-cho, Chuo-ku, Kobe, Hyogo 650 0047
Tel: 078-304-7581 E-mail: Hirooka.Masahiko@technopro.com

TOPPAN Inc.

[Corporate Profile] Creating new value by overcoming all social issues

- Business domain -

INFORMATION & COMMUNICATION Creative communication and information management	LIVING & INDUSTRY Living and industrial materials and functional materials	ELECTRONICS Electronic devices and devices

Specific initiatives in the medical and pharmaceutical fields

Becoming a leading company solving social issues worldwide through DX and SX

① "DX Solutions" to solve problems at medical institutions and enable DX in medical care

◆Support for DX in medical care

- **Development of IC tag labels that can be used in frozen environments**
- **Improvement of operations with IC tag systems**
- **Realization of paperless and real-time systems using electronic paper**
- **Visualization of temperature management using on-tray system tags**

② Enhancing functionality, environmental friendliness, and value through sustainability-conscious packaging (SX)

◆In-vitro diagnostics manufacturing contract business

- **Our manufacturing contract business is underway at our manufacturing base in Kasai City, Hyogo Prefecture.**
- **We are expanding our scope beyond in-vitro diagnostics.**

③ Contributing to the realization of future medical care through social implementation of new healthcare technologies

◆3D cell culture invivoid ®
Innovative for next-generation drug discovery
Tissue engineering technology

◆Digital ICA® High-Sensitivity Fluorescence Detection Technology
Detecting DNA and other biomolecules by distributing them one molecule at a time

◆Films that can be applied to the skin
Films that can be applied directly to the skin and can be printed (designed) on the surface



Three-dimensional Tissue

If you want to solve on-site problems with DX and SX, please leave it to TOPPAN!

TOPPAN Corporation
IoT Solution Business Unit Technical Sales Dept.

Junya Kobayashi

MOBILE : 080-4790-9679 email : junya.kobayashi@toppan.co.jp

Nakanoshima Festival Tower, 2-3-18 Nakanoshima, Kita-ku, Osaka 530 0005, Japan

URL:https://www.toppan.com/ja/

NARD Institute, Ltd.

Custom Synthesis by NARD institute, LTD.

We aim to solve your problems, we conduct research and development support.

- Synthesis of non-commercial compounds
- Design of original functional molecules
- Manufacturing under

  ISO standards and

  GMP guidelines

Technical keywords

- Compounds for media supplementation
- Fluorescent labeling
- Cell scaffolding Material
- Hydrophilic polymer
- Hydrogel
- Pharmaceuticals
- Manufacturing Process Development

◇ FTE research contract

◇ Scale-up production*

*Conducted at NARD Chemicals, Ltd.

NARD Institute, Ltd.

Corporate Research Department

2 -6 -1 Nishinagasu-cho, Amagasaki-shi, Hyogo 660 0805

TEL: 06-6482-7024

https://www.nard.co.jp/

Please feel free to contact us for your request!

Nissin Corporation

Company Profile

Yokohama Head Office: 6-81, Onoe-Cho, Naka-ku, Yokohama, Kanagawa

Tokyo Head Office: 1-6-4, Kojimachi, Chiyoda-ku, Tokyo

Founded: December 14, 1938 (Showa 13)

Capital: 6,097million yen (as of March 31, 2026)

Business: International transportation, domestic transportation, warehousing, customs clearance, moving, travel, etc.

Number of domestic locations: 129 (as of March 31, 2026)

Number of overseas locations: 23 countries & areas 150 offices (29 local subsidiary) (as of the end of March 2026)

Service Overview

- Domestic temperature control truck transportation
- International GDP transportation (air and sea)
- Domestic/Overseas thermal packaging
- Exhibition transportation
- Trade consulting (export/import consultation)
- Export/Import customs clearance
- **Pharmaceutical** storage in GDP-certified warehouses

Nissin in fiscal 2025 ・・・・

- We have opened VIXELL stations in Narita, Osaka Nanko, and Chicago.
- We conducted a demonstration experiment using the Shinkansen.
- We have also obtained GMP license in the Kanto region.

Service performance

- Investigational drug GDP transport by constant temperature trucks
- Long-term temperature maintenance transport using Panasonic's VIXELL ® (temperature logger with GPS function)
- Marine transport of pharmaceuticals using Reefer Container
- Transport of products exhibited at medical exhibitions
- Accompanying consultations with customs and authorities
- Consulting on how to fill out documents in the field of trade practice and acquisition of regulatory authority
- Wholesale distribution business license and drug tax increase license Storage in warehouse (acquisition of GDP certification)
- Thermal storage agent temperature control service

DX Promotion Department, Pharmaceutical Business Promotion Section, Nissin Corporation

Tsuyoshi Shijubo, Yasushi Maegawa

1 -6 -4 Kojimachi, Chiyoda-ku, Tokyo 102 8350

Tel: 81-(0)3-3238-6549 mailto: nissin_medical@nissin-tw.com

https://www.nissin-tw.com/

What we would like to consider in the medical field ・・・

Validation of international transport of cells by multiple companies

Japan Blood Products Organization

Philosophy

Bridging Good Faith and Healthcare

Through blood products derived from voluntary non-remunerated blood donations, we contribute to people's health with the highest sense of ethics and responsibility.

Purpose of Establishment

Delivering blood products derived from voluntary non-remunerated blood donations to patients in a safe and secure form. This is the unchanging mission of those involved in blood services. We place the highest priority on enhancing the safety and reliability of plasma fractionated products, aiming to achieve domestic self-sufficiency and stable supply through donated blood. Our organization was established on June 1, 2012, and commenced operations on October 1 of the same year. Based on the basic idea that blood should not be sold commercially, we will pave the way for a new history of the plasma fractionation business as a non-profit, general incorporated association. As those who handle blood products made from voluntary non-remunerated blood, we aim to be an organization that protects public health with a high sense of ethics and responsibility

R&D

We manufacture plasma fractionated products by pooling valuable plasma from blood donors and are pursuing the potential of blood products from limited resources. Since human blood is used as a raw material, it is necessary to reduce the risk of viral infections as much as possible, especially from a safety perspective. A distinctive feature of our organization is our laboratory dedicated to conducting research on safety measures against infectious pathogens.

Structure of the Central Research Laboratory

Research Section I: Promotion of research and development for the creation of new products, etc.
Research Section II: Promotion of research and development for toward maximizing the value of existing products.
Research Section III: Research on safety and toxicity evaluations regarding infectious pathogens toward ensuring the safety of plasma fractionated products.

We create new value from donated blood.

As part of our pursuit of the potential of limited resources, we are seeking opportunities to apply plasma components to regenerative medicine substrates. We will also contribute to efforts toward commercialization by applying our experience, knowledge, and technological capabilities regarding safety.

Contact:
Central Research Laboratory, Japan Blood Products Organization
Kobe KIMEC Center Building 8F, 1-5-2 Minatojima-minamimachi, Chuo-ku, Kobe, 650 0047
TEL: 078-599-5095/email: info-jb-reslabo-gr@jbpo.or.jp
URL: https://www.jbpo.or.jp/

CORE MESSAGE

Implementing next-generation medicine through the fusion of Bio & Digital.

A research partner that owns both stem-cell wet science and AI-driven dry analytics in-house — built to solve real-world challenges in drug discovery and regenerative medicine.

Concept — Why NextGeM

In drug discovery and regenerative medicine, the gap between the **volume of wet-lab data** and the **speed and depth of analytical interpretation** is often what stalls a project. NextGeM closes that gap by running **stem-cell wet research (Kobe)** and **AI analytics (Tokyo)** under one roof — advancing experiment and analysis as a single workflow, dramatically shortening verification cycles, and carrying the work through to **regulatory-ready outcomes**.

Two Core Solutions — Contract & Joint Research Areas

BIO

Stem Cell Research Services

CONTRACT R&D

- **Mechanistic analysis of hematopoietic stem cells** (self-renewal & differentiation)
- **Advanced culture & differentiation** — protocol design and optimization
- **Pre-clinical evaluation support** for regenerative medicine candidates
- **Custom assay development** tailored to client projects

DIGITAL

AI Analytics Solutions

AI / ML FOR LIFE SCIENCE

- **Image-based cell evaluation** (automated morphology & quality scoring)
- **Diagnostic & prognostic algorithm** development
- **SaMD (Software as a Medical Device)** development support
- **Research data integration &** bioinformatics platforms

Strength — One-stop acceleration of R&D

Wet Experiments KOBE LAB ▶ **Data Analytics** TOKYO LAB ▶ **Implementation & Regulatory** INTEGRATED

Our Kobe Wet Lab (Port Island) and Tokyo Data Lab (Shibuya) operate as one team, delivering **experiment-to-implementation as a single contract**. Friction across vendors disappears, and **research speed and precision improve dramatically**.

KEY TRACK RECORD

- **AMED-funded research** — awarded and successfully delivered
- **Joint research projects** with leading corporations (multiple ongoing)
- **Regulatory-ready execution** in regenerative medicine

NEXTGEM
NEXT GENERATION OF MEDICINE

CONTACT
hello@nextgem.jp
For contract & joint research inquiries

LOCATIONS
Tokyo Data Lab — 1-5-13 Jinnan, Shibuya, Tokyo
Kobe Wet Lab — Kobe Center for Medical Innovation, 6-3-5 Minatojima- Minamimachi, Chuo-ku, Kobe

nextgem.jp/en/

Vision Care Group

For the benefit of patients with retinal diseases from Kobe to the world

Utilizing research results of the world's first iPS cell-based retinal cell transplantation to develop new treatments

The Vision Care Group, which develops treatments for retinal diseases, was established based on the Kobe Eye Center concept proposed by President Masayo Takahashi and fellow ophthalmologists to advance the patient well-being employing state-of-the-technologies including those from her RIKEN teams. As subsidiaries for specific purposes, VCGT Inc. was established in August 2020 and VCCT Inc. in March 2021, focusing on the commercialization of gene and cell therapies, respectively. With the mission of "A cure for all outer retinal diseases", we are conducting joint research with Kobe City Eye Hospital. In addition to promoting research and development for the realization of gene therapy and regenerative medicine, and bringing our research technology to practical use, we are also working to create new businesses as a liaison for the Eye Center.

Vision Care Inc. performs the same research division as the head office functions, and the purpose specific subsidiary of gene and cell therapy functions.



Vision Care Inc.
- Purpose Management of subsidiaries
- Research and development in ophthalmology and regenerative medicine
- Consulting in ophthalmology and regenerative medicine
- Employment and livelihood support for low vision

VCGT Inc.
- Gene Therapy Development
- Manufacture, sales, export and import of products related to gene therapy
- Acquisition, ownership, licensing, transfer, and management of intellectual property such as industrial property rights and copyrights.

*RIKEN Venture Certification

VCCT Inc.
- Cell Therapy Development
- Manufacture, sales, export and import of products related to regenerative medicine
- Acquisition, ownership, licensing, transfer, and management of intellectual property such as industrial property rights and copyrights.

*RIKEN Venture Certification

Development pipeline

Product	Cell and genetic technology
MastCT-01,03	Allogenic iPS cell-derived retinal pigment epithelium (RPE)
MastCT-02	Autologous iPS cell-derived retinal pigment epithelium (RPE)
MastCT-04,05	Retinal sheet derived from allogenic iPS cells
MastGT-01	Retinitis pigmentosa gene therapy


「日本丸」神戸港入港 ©神戸市港湾局

The development number "Mast" was named in the hope that it will become a mainstay in the treatment of outer retinal diseases and advance in the ocean of medicine.

＜Release＞
- ■2026.02.27 VCCT Inc. Concludes Capital and Business Alliance Agreement with Kuraray Co., Ltd.（In Japanese）
- ■2025.12.18 VCCT Inc. Joins Impact Startup Association as a Full Member（In Japanese）
- ■2025.07.28 VCCT Inc. Selected for METI's FY2025 Go-Tech Program（In Japanese）
- ■2025.05.12 VCCT Inc. and Eisai Co., Ltd. Enter into Collaborative Research Agreement to Develop Retinal Organoid-Based Drug Toxicity Testing Platform


Kobe Eye Center


LabDroid Maholo ©Robotic Biology Institute Inc.


Cell processing center FiRst


Kobe Eye Center Vision Park

Vision Care Group　https://www.vision-care.jp/
Adress：Kobe Eye Center 5F, 1-8, Minatojima-minamimachi, Chuo-ku, Kobe, 650-0047
(Inquiries) info@vision-care.jp

HITACHI

Hitachi, Ltd. R&D Group

Hitachi, Ltd. has been leveraging open innovation at its Hitachi Kobe Lab, established in 2017, to contribute to the spread of regenerative medicine and gene/cell therapy. The lab focuses on two key technologies:

1. **Automated Cell Culture Equipment:** We developed a fully closed-system automated cell culture technology, and in 2019, Hitachi High-Tech commercialized the iACE2 automated cell culture equipment. This system enables large-scale culture and a highly sterile environment, and has been applied to the production of iPS cell-derived cell therapies. In 2025, Hitachi High-Tech commercialized the iACE mini, a compact culture system suitable for cancer immunotherapy.
2. **Innovative CAR Sequence Design Technology (DesignCell Development platform) :** Combining proprietary gene-generation AI and high-throughput automated experiments, we successfully create high-performance novel CAR sequences in laboratory settings.

Hitachi provides solutions across the group, supporting growth in regenerative and cell therapies.

①Automated Cell Culture Equipment

iACE2 (ACC-200)

＜ Core strengths ＞
- •Mass cell production
- •Automation of expansion and differentiation
- •Sterile environment by single-use closed module

iACE mini (SCC-100)

＜ Core strengths ＞
- ・Supports commercial vessels (e.g., G-Rex100M-CS) for immune cell culture.
- ・Automate cell seeding, expansion, supernatant sampling, and cell collection.

②DesignCell Development platform



＜ Core strengths ＞
(Gene Design; Design)
：Discovery space (10^8 CAR diversity)
(Gene Introduction; Build, Functional Evaluation; Test)
：An automated HT evaluation system
(Correlation Analysis; Learn)
：Original sequence generating AI

⇒ Promising CAR sequences can be quickly obtained through DBTL cycle

Reference
- iACE2, iACE mini automated cell culture system <https://www.hitachi-hightech.com/global/en/products/healthcare/treatment/regenerative-medicine/>
- Pioneering technologies and systems for next-generation regenerative and cell therapies <https://rd.hitachi.co.jp/_ct/17685531>
- Design Cells: Designed Cells Cure Diseases <https://www.hitachi.com/en/insights/articles/designed-cell/>

*iACE is a registered trademark of Hitachi-hightech in Japan *Part of the contents introduced in this article were performed at the Japan Agency for Medical Research and Development (AMED) "JP 18be0104016 " .

Hitachi Kobe Laboratory, Research and Development Group, Hitachi, Ltd. Address: 6-3-7 Creative Lab Kobe Suite 304, Minatojima -minamimachi, Chuo -ku, Kobe, Hyogo 650 0047
Contact: Hiroko Hanzawa (070-3952-5338/ hiroko.hanzawa.hr@hitachi.com)
Tomohiko Okuda (080-7764-4269 / tomohiko.okuda.ax@hitachi.com)

Phicell Corporation

We support product development where reliability is paramount, by providing safe storage solutions for cells, specimens, and other materials.

◆ Storage and Transportation Service Overview



◆ Storage Facilities and Serving Temperature

Liquid Nitrogen Vapor Phase Storage | Ultra-Low Temperature Storage | Low Temperature Storage | Refrigerated storage

◆ Storage Target

- Cell
- Investigational Drug
- Medium
- Slide Specimen
- Vaccine
- Nucleic Acid
- Clinical Specimen
- Antibody
- Reference/Retention samples
- Virus Vector

[Contact Information]

PHICELL

Phicell Corporation

Kobe KIMEC Center Building 2F, 1-5-2, Minatojima-Minamimachi, Chuo-ku, Kobe shi, Hyogo

HP : https://phicell.co.jp/ E-mail : contact@phicell.co.jp

Bourbon Corporation

[Overview of Initiatives/Related Products]

In Bourbon, we have developed a multipotent stem cell research program as part of our health science research. By utilizing our culture technology and broad knowledge of sugar, a major ingredient in foods, we are engaged in fundamental technological development and research with the aim of contributing to the development of regenerative medicine research through safe and secure control of cell proliferation by sugar.

The **“Xyltech™ Series”** of culture medium for regenerative medicine is a novel cell culture system to control cell proliferation rate. These products are provided by Bourbon Biomedical Advanced Research Laboratories, Inc., a group company of Bourbon Corporation, and we propose various applications, such as reducing passaging frequency, short-term cell storage, and controlling cell density during transport.

[Product Lineup]

Human pluripotent stem cells

Human pluripotent stem cells proliferation control medium
【Cell proliferation suppression】
Xyltech™ BOF-01

Human fibroblasts

Serum-free complete synthetic culture medium for human fibroblasts
【Cell proliferation suppression】
Xyltech™ H-Fbro-01

Serum-free complete synthetic culture medium for human fibroblasts【Cell proliferation】
Xyltech™ Growth H-Fbro

Human mesenchymal stromal cells

Serum-free complete synthetic medium for human Mesenchymal Stromal Cells
【Cell proliferation suppression】
Xyltech™ MSC-02 Animal-Free

Serum-free complete synthetic medium for human Mesenchymal Stromal Cells【Cell proliferation】
Xyltech™ Growth MSC

For more information on the Xyltech™ series culture medium, please visit the following website.

Bourbon Biomedical Advanced Research Laboratories, Inc.

HP: https://www.bourbon-barl.co.jp/eg/
Contact: support@bourbon-barl.co.jp

[Contact]
Bourbon corporation
Laboratory for Advanced Health Sciences,
Advanced Research Institutes, Takizawa
TEL: 0263-88-7848
E-mail: takizawa-sak@bourbon.co.jp

BOURBON ブルボン

VectorBuilder
Where Better Science Begins

From Research to Therapy
Leveraging Cell and Gene Therapy Drug Development

VectorBuilder is a full-service CDMO providing comprehensive support for cell and gene therapy development. From vector design and process development to GMP manufacturing and quality control, we support your entire pipeline.

Highlights

Good Vector Practice
Intelligent GMP-grade vector design for therapeutics—maximizing efficacy, safety, and manufacturability.

Highest Quality and Consistency
State-of-the-art GMP facilities ensuring the highest purity and consistency at every step.

Regulatory Support
From strategy consultation for IND-enabling documentation to CMC documentation for clinical trial.

Technology Transfer
Detailed bill of materials, well-documented process, and fully qualified analytical methods.

Full-Service CDMO Services Offered

Our comprehensive quality system covers every aspect of our GMP manufacturing process including facilities, supplies, production, fill/finish, storage, in-process and release QC, and personnel.

CDMO Services Overview

Process Development	Analytical Development	Cell Banking	GMP Manufacturing	Fill/finish
Vector Optimization	QC Assays	Master Cell Banks (MCBs)	Plasmid DNA	Manual line
Upstream PD (USP)	Stability Studies	Working Cell Banks (WCBs)	Viral vector	Automated line
Downstream PD (DSP)			IVT RNA and LNP	

VectorBuilder's Proprietary Technologies ~ GVP (Good Vector Practice) ~
Supporting advanced gene therapy development by enhancing: Efficacy | Safety | Manufacturability

At VectorBuilder, we provide cutting-edge solutions that propel research and development in cell and gene therapy through solving every bottleneck in gene delivery.
Built on three cornerstones—**Efficacy, Safety, and Manufacturability**—our innovations enhance therapeutic performance and safety while enabling faster, cost-effective path to commercialization.

VectorBuilder Inc.

Global headquarter 1010 W. 35th street, Suite 515, Chicago, IL 60609, USA
Japan headquarter 2-12-16, Shin-Yokohama, Kouhoku-ku, Yokohama, Kanagawa, Japan
Kobe office 1-5-2 Minatojima Minami-machi, Chuo-ku, Kobe, Hyogo, Japan

website

Order online today https://www.vectorbuilder.jp

Contact us at service-jp@vectorbuilder.com

HEALIOS K.K.

Our mission is to foster a "Life Explosion" that enriches the lives of people around the world. In pursuit of this mission, we maintain the goal of delivering cures and hope to patients with unmet medical needs.

Somatic Stem Cell Regenerative Medicine

【Inflammatory Conditions】

HLCM051	ARDS	Invimestrocel	Global (USA)	Japan: Japan: Conditional and Time-limited ARDS Approval Application in preparation Global: Preparing for Phase 3 study
	Ischemic Stroke			Japan: Aiming for Conditional and Time-limited Approval Application Global：Fast Track and RMAT Designation



Development of cellular pharmaceuticals for Acute Respiratory Distress Syndrome (ARDS) and Ischemic Stroke using the stem cell product HLCM051.

iPSC Regenerative Medicine

【Immune Oncology】

HLCN061	Solid tumors	eNK	Global	Akatsuki Therapeutics leads research and development
—		CAR-eNK	Global	



Research and development of cancer therapies using engineered NK cells (eNK cells) with enhanced anti-cancer activity by combining iPS cell technology and gene-editing technology.

【Replacement Therapy】

HLCR011	RPE Tear Age-related Macular Degeneration	Retinal Pigment Epithelium (RPE)	Japan	Joint development with RACTHERA Co. Ltd.



・iPSC Platform

Development of allogeneic iPS cells (Universal Donor Cell: UDC) with minimized immune rejection risk irrespective of HLA type, leveraging gene-editing technology.

Differentiation and induction of various cells from iPS cells to develop new treatment methods for intractable diseases.

Company Overview

Company Name	**HEALIOS K.K.（Tokyo Stock Exchange Growth Market Securities Code: 4593）**
Head Office	**Hibiya Mitsui Tower 12F, WORK STYLING, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006, Japan**
Kobe Research Institute	**Kobe KIMEC Center Bldg. 3F 1-5-2 Minatojima-Minamimachi Chuo-ku, Kobe, Hyogo 650-0047, Japan**
URL	**https://www.healios.co.jp/**
Contact	**info@healios.jp**

2025.05

MATRIXOME

Creating the Future of Regenerative Medicine

iMatrix

perLAM

Innovating the next generation of cell culture with Laminin E8 fragments and perlecan-conjugated laminin E8

- Our unique lineup of substrates comprehensively covers the entire Laminin α-chain domain
- Superior performance in adhesion, proliferation, and differentiation efficiency compared to conventional substrates
- Trusted by researchers worldwide — from basic research to GMP-compliant clinical grade applications

Matrixome, Inc.

Sales Department: Apurva K.
TEL: 06-6877-0222

For product inquiries, please contact us on our website.

Mitsui Soko Group's Regenerative Medicine Services

MITSUI-SOKO GROUP

Regenerative medicine, Investigational drug, cell, etc. Advanced Logistics Service

One-stop Operation
GCTP facility+domestic/overseas transport



1. Consigned logistics for 8 of 23 approved regenerative medicine products in Japan. (as of the end of March 2026)
2. Figure Achieved high ratings from medical institutions in terms of transport quality in domestic logistics.
3. We can provide one-stop service for all processes in the supply chain from Japan to overseas.
4. Acquired regenerative medicine product manufacturing license (packaging, labeling and storage categories) in East and West.

- BCP measures to realize stable supply are also possible
- Packaging and labeling work can be outsourced
- Free selection of distributors and CMO for service-product separation

Service Overview

Storage
High-quality operation conforming to GCTP (multiple locations)

High-quality control at low temperature storage

[Storage in liquid nitrogen tanks, freezers, etc.]

Room temperature exposure time control, etc.

[Incoming and outcoming operations in vapor phase environments, etc.]

[Environmental maintenance]
Validation, periodic inspection, temperature, etc.

Transport
Low-temperature transport utilizing Our company's proprietary shipping containers (domestic and overseas)

- Carrier arrangement according to transportation temperature and transportation section
- Formulation of transportation procedures [SOP]
- Support for overseas transportation (including import and export operations)
- Compliance with GDP guidelines



Storage Facility
Regenerative medicine logistics center
『MEDiUS-East』@Tokyo
『MEDiUS-West』@Kobe

- BCP measures such as quake-absorbing structure and in-house power generator
- Security Management
- Packaging, labeling, and inspection services

GCTP License Conplianced

Transport Container
Cryogenic transport container
『MEDiSTAR EX』

- Cryogenic conditions below -150 °C maintained for 7 days
- Structure to minimize vibration
- Temperature recording/vibration recording data can be submitte

Airine-approved electronic devices are used to monitoring temperature and shock in the container.

Logistics

Pharma & Medical Innovation

Contact

MITSUI-SOKO HOLDINGS Co., Ltd.
Business Development Division

Smartphone Contact Form

19-21, Nihonbashi Hakozaki-cho, Chuo-ku, Tokyo 103-0015, Japan TEL 03-6775-3098

RACTHERA Co., Ltd.

RACTHERA Co., Ltd. is a joint venture established by Sumitomo Chemical and Sumitomo Pharma to accelerate the development and commercialization of regenerative and cellular medicine.

- ☐ Leveraging Sumitomo Pharma's pharmaceutical business foundation together with Sumitomo Chemical's industrialization, analytical, and quality management expertise to accelerate research, development, and commercialization
- ☐ Collaborating closely with S-RACMO, a group company with strengths in cell production and manufacturing technologies, to provide an end-to-end platform from R&D to commercial manufacturing.



As a frontrunner in regenerative and cellular medicine, we deliver new value made possible only by regenerative medicine.



Regenerative & Cellular medicine

Restoring tissues and cells damaged by disease or injury

Main Pipeline Products (As of the end of March 2026)

- Dopaminergic progenitor cells (Parkinson's disease) | Conditional and Time-Limited Approval
- Retinal pigment epithelial cells (Retinal pigment epithelial tear) | Phase1/2
- Retinal sheet (Retinitis pigmentosa) | Phase1/2
- Neural progenitor cells (Spinal cord injury) | Clinical research
- Nephron progenitor cells (Kidney failure) | Pre-clinical

RACTHERA

Break the Boundaries, Deliver the Future

■Address 5F Kobe KIMEC Center Building, 1-5-2 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo 650 0047
■Contacts Ryo Yamaguchi, Katsumi Iwata
■E-mail contact@racthera.co.jp

CM Plus Corporation

Your seamless partner in regenerative medicine: From early discovery to post-market solutions

One-stop consulting by seasoned experts, covering everything from commercialization to facility construction



Feature 1:
Highly Experienced Expert Team

Supported by a dedicated team of regenerative medicine consultants, engineers, and regulatory experts.

Feature 2:
QMS / GCTP Framework Establishment

Robust support for regulatory compliance, including organizational setup, training, supplier management, and GAP analysis.

Feature 3:
Facility and Equipment (CPC) Optimization

Comprehensive hardware and software support, covering facility planning, diagnostics, and validation assistance.

Main support menu

- Commercialization Roadmaps
- Regulatory Affairs Consulting (Development & Submissions)
- QMS & GCTP Organizational Design
- CPC (Cell Processing Center) Setup
- Validation Assistance
- Global Expansion & Multilingual Support
- Mock Inspections & Audit Readiness

Consult with us on your regenerative medicine challenges

CM Plus Corporation
https://cm-plus.co.jp/en/
Mail : info@cm-plus.co.jp

Mediford Corporation

Safety Study Services for Regenerative Medicine

Comprehensive services in facilities compliant with GLP for regenerative medical products

Study type	Animals, Kits, etc.
Single-dose toxicity	• Mice (ICR, BALB/c, etc.) • Nude mice • SCID mice • NOD-SCID mice • NOG mice • NSG mice • Rats (SD) • Nude rats
Repeated-dose toxicity	
Tumoringenicity	• Nude mice • SCID mice • NOD-SCID mice • NOG mice • NSG mice • Nude rats
Soft agar colony formation assay	• CytoSeleCtM 96-well cell transformation assay • Digital soft agar colony formation assay
Analysis of cell growth characteristics	Long-term culture using medium and culture method suitable for the product
Safety pharmacology	• Central nervous system • Respiratory system • Cardiovascular system
Others	Other study types and animal species are also available based on your requirements.

* We also offer efficacy study services.

IVIS Lumina Series III

Time-course monitoring of biodistribution in the same subject

An in vivo imaging system that captures extremely weak bioluminescence and fluorescence using a highly sensitive CCD camera



● Contact Us

Mediford Corporation

medf-dds-sales@gg.mediford.com

www.mediford.com/en/

36-1 Shimizu-cho, Itabashi-ku, Tokyo 174-0053, Japan

mediford
A Member of PHC Group

KBIC
KOBE Biomedical Innovation Cluster

Publisher
Foundation for Biomedical Research and Innovation at Kobe
Translational Research Informatics Center 2F 1-5-4 Minatojima Minamimachi,
Chuo-ku, Kobe City, Hyogo, 650-0047, JAPAN
E-mail : saisei-benkyo@fbri.org

2026.06